PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24637190-13	2014	Compared to CCl4 model group, Sorafenib and XFZY decreased alpha-SMA, collagen I, CD31, VEGF, VEGFR-2, HIF-1alpha and ADMA, and increased the expression of DDAH1.	Sorafenib	30-39	chemokine (C-C motif) ligand 4	Mus musculus	12-16	
34811833-8	2022	RESULTS: Sorafenib attenuated liver injury and ECM accumulation in CCl4 -induced fibrotic livers, accompanied by reduction of SLC7A11 and GPX4 proteins.	Sorafenib	9-18	chemokine (C-C motif) ligand 4	Mus musculus	67-71	
23948302-0	2013	STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.	Sorafenib	96-105	chemokine (C-C motif) ligand 4	Mus musculus	30-34	
23948302-2	2013	We have taken advantage of this data to focus on the mechanisms of action of a unique multi-kinase inhibitor, coined sorafenib, on CCl4-induced murine liver fibrosis, including the effects of this agent in models of both acute and chronic CCl4-mediated pathology.	Sorafenib	117-126	chemokine (C-C motif) ligand 4	Mus musculus	131-135	
23948302-2	2013	We have taken advantage of this data to focus on the mechanisms of action of a unique multi-kinase inhibitor, coined sorafenib, on CCl4-induced murine liver fibrosis, including the effects of this agent in models of both acute and chronic CCl4-mediated pathology.	Sorafenib	117-126	chemokine (C-C motif) ligand 4	Mus musculus	239-243